Klaria Pharma Holding AB (DE:6FN)
FRANKFURT:6FN
Want to see DE:6FN full AI Analyst Report?
6FN Stock Chart & Stats
€0.06
>-€0.01(-25.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-25.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)8.58K
Market Cap
€21.50M
Enterprise Value€311.56M
Total Cash (Recent Filing)€342.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.32
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding245,976,150
10 Day Avg. Volume650
30 Day Avg. Volume8,579
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€2.22M
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-delivery PlatformKlaria’s mucoadhesive oral film is a platform technology that can be applied across multiple indications. A durable platform creates potential for repeatable product launches, licensing deals, and faster systemic uptake benefits that differentiate offerings and support long-term partner interest.
Debt Elimination By 2025Reducing reported debt to zero materially lowers interest burden and default risk, improving financing flexibility. For a cash-burning drug developer, deleveraging is a lasting structural improvement that makes future equity or partnership financings less encumbered by prior loan covenants.
Partner-focused Commercialization StrategyA stated strategy to commercialize via partners lets Klaria leverage external sales, regulatory and distribution capabilities. For a small-company R&D model, partnering is a durable route to market that reduces capex and operating leverage needs while accelerating patient access and revenue scaling if candidates succeed.
Bears Say
Severe Persistent UnprofitabilityExtremely negative margins reflect that core operations are not generating profit and are destroying capital. Persistent unprofitability forces repeated external financing, increases dilution risk, and undermines the company's ability to sustain clinical development without clear near-term licensing or funding events.
Negative Shareholders' EquityNegative equity signals accumulated losses or significant dilution and materially reduces balance sheet resilience. It constrains borrowing capacity, may deter strategic partners or counterparties, and increases the likelihood of restructuring or highly dilutive recapitalizations absent operational turnaround or major financing.
Consistent Negative Operating Cash FlowChronic negative operating cash flow and increasing burn mean the company depends on external funding for operations and trials. This structural cash shortfall can delay development programs, force unfavorable partner terms or financing, and raises execution risk until sustainable cash generation is achieved.
6FN FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was €0.03 and its highest was €0.12 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is €21.50M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is May 08, 2026 which is in 8 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on Feb 20, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6FN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.